Stem cell therapy for neonatal brain injury: Perspectives and Challenges

Annals of Neurology

Volumn 70, Issue 5, 2011, Pages 698-712

  Titomanlio, Luigi ^a,b,c   Kavelaars, Annemieke ^d   Dalous, Jeremie ^a,b,c   Mani, Shyamala ^e   El Ghouzzi, Vincent ^a,b,c   Heijnen, Cobi ^d   Baud, Olivier ^a,b,c   Gressens, Pierre ^a,b,c,f  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PremUP   (France)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e INDIAN INSTITUTE OF SCIENCE   (India)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN INJURY; BRAIN ISCHEMIA; CEREBRAL PALSY; CLINICAL TRIAL (TOPIC); EMBRYONIC STEM CELL; ENGRAFTMENT; HUMAN; IMMUNE RESPONSE; MESENCHYMAL STEM CELL; NERVE REGENERATION; NEURAL STEM CELL; NEURONAL CEROID LIPOFUSCINOSIS; NEUROPROTECTION; NONHUMAN; PELIZAEUS MERZBACHER DISEASE; PERIVENTRICULAR WHITE MATTER DAMAGE; PLURIPOTENT STEM CELL; PREMATURITY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; WHITE MATTER;

ANIMALS; ANIMALS, NEWBORN; BRAIN INJURIES; CELL DIFFERENTIATION; CEREBRAL PALSY; DISEASE MODELS, ANIMAL; EMBRYONIC STEM CELLS; HUMANS; NEURAL STEM CELLS; STEM CELL TRANSPLANTATION; STEM CELLS; TREATMENT OUTCOME;

EID: 83255164111     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22518     Document Type: Article

References (184)

1. Allen MC,. Neurodevelopmental outcomes of preterm infants. Curr Opin Neurol 2008; 21: 123-128.
2. Robertson CM, Watt MJ, Yasui Y,. Changes in the prevalence of cerebral palsy for children born very prematurely within a population-based program over 30 years. JAMA 2007; 297: 2733-2740.
3. Vincer MJ, Allen AC, Joseph KS, et al. Increasing prevalence of cerebral palsy among very preterm infants: a population-based study. Pediatrics 2006; 118: e1621-e1626.
4. Wilson-Costello D, Friedman H, Minich N, et al. Improved neurodevelopmental outcomes for extremely low birth weight infants in 2000-2002. Pediatrics 2007; 119: 37-45.
5. Volpe JJ,. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr Res 2001; 50: 553-562.
6. Craig A, Ling Luo N, Beardsley DJ, et al. Quantitative analysis of perinatal rodent oligodendrocyte lineage progression and its correlation with human. Exp Neurol 2003; 181: 231-240.
7. Back SA, Han BH, Luo NL, et al. Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci 2002; 22: 455-463.
8. Inder TE, Warfield SK, Wang H, et al. Abnormal cerebral structure is present at term in premature infants. Pediatrics 2005; 115: 286-294.
9. Volpe JJ,. Encephalopathy of prematurity includes neuronal abnormalities. Pediatrics 2005; 116: 221-225.
10. Kesler SR, Vohr B, Schneider KC, et al. Increased temporal lobe gyrification in preterm children. Neuropsychologia 2006; 44: 445-453.
11. Leviton A, Gressens P,. Neuronal damage accompanies perinatal white-matter damage. Trends Neurosci 2007; 30: 473-478.
12. Marlow N, Wolke D, Bracewell MA, Samara M,. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005; 352: 9-19.
13. O'Shea M,. Cerebral palsy. Semin Perinatol 2008; 32: 35-41.
14. Silbereis JC, Huang EJ, Back SA, Rowitch DH,. Towards improved animal models of neonatal white matter injury associated with cerebral palsy. Dis Model Mech 2010; 3: 678-688.
15. Zhen G, Dore S,. Optimized protocol to reduce variable outcomes for the bilateral common carotid artery occlusion model in mice. J Neurosci Methods 2007; 166: 73-80.
16. Howells DW, Porritt MJ, Rewell SS, et al. Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J Cereb Blood Flow Metab 2010; 30: 1412-1431.
17. Popp A, Jaenisch N, Witte OW, Frahm C,. Identification of ischemic regions in a rat model of stroke. PLoS One 2009; 4: e4764.
18. Hagberg H, Peebles D, Mallard C,. Models of white matter injury: comparison of infectious, hypoxic-ischemic, and excitotoxic insults. Ment Retard Dev Disabil Res Rev 2002; 8: 30-38.
19. Follett PL, Deng W, Dai W, et al. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. J Neurosci 2004; 24: 4412-4420.
20. Vannucci RC, Connor JR, Mauger DT, et al. Rat model of perinatal hypoxic-ischemic brain damage. J Neurosci Res 1999; 55: 158-163.
21. Vannucci SJ, Hagberg H,. Hypoxia-ischemia in the immature brain. J Exp Biol 2004; 207: 3149-3154.
22. Pang Y, Cai Z, Rhodes PG,. Disturbance of oligodendrocyte development, hypomyelination and white matter injury in the neonatal rat brain after intracerebral injection of lipopolysaccharide. Brain Res Dev Brain Res 2003; 140: 205-214.
23. Fan LW, Tien LT, Mitchell HJ, et al. Alpha-phenyl-n-tert-butyl-nitrone ameliorates hippocampal injury and improves learning and memory in juvenile rats following neonatal exposure to lipopolysaccharide. Eur J Neurosci 2008; 27: 1475-1484.
24. Lehnardt S, Lachance C, Patrizi S, et al. The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J Neurosci 2002; 22: 2478-2486.
25. Cai Z, Pan ZL, Pang Y, et al. Cytokine induction in fetal rat brains and brain injury in neonatal rats after maternal lipopolysaccharide administration. Pediatr Res 2000; 47: 64-72.
26. Wang X, Rousset CI, Hagberg H, Mallard C,. Lipopolysaccharide-induced inflammation and perinatal brain injury. Semin Fetal Neonatal Med 2006; 11: 343-353.
27. Johnston MV,. Excitotoxicity in perinatal brain injury. Brain Pathol 2005; 15: 234-240.
28. Deng W, Pleasure J, Pleasure D,. Progress in periventricular leukomalacia. Arch Neurol 2008; 65: 1291-1295.
29. Inglis WL, Semba K,. Discriminable excitotoxic effects of ibotenic acid, AMPA, NMDA and quinolinic acid in the rat laterodorsal tegmental nucleus. Brain Res 1997; 755: 17-27.
30. Cao Q, Benton RL, Whittemore SR,. Stem cell repair of central nervous system injury. J Neurosci Res 2002; 68: 501-510.
31. Conti L, Cataudella T, Cattaneo E,. Neural stem cells: a pharmacological tool for brain diseases? Pharmacol Res 2003; 47: 289-297.
32. Pluchino S, Zanotti L, Rossi B, et al. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 2005; 436: 266-271.
33. Windrem MS, Schanz SJ, Guo M, et al. Neonatal chimerization with human glial progenitor cells can both remyelinate and rescue the otherwise lethally hypomyelinated shiverer mouse. Cell Stem Cell 2008; 2: 553-565.
34. Kim SU, de Vellis J,. Stem cell-based cell therapy in neurological diseases: a review. J Neurosci Res 2009; 87: 2183-2200.
35. Pimentel-Coelho PM, Mendez-Otero R,. Cell therapy for neonatal hypoxic-ischemic encephalopathy. Stem Cells Dev 2010; 19: 299-310.
36. Sato Y, Nakanishi K, Hayakawa M, et al. Reduction of brain injury in neonatal hypoxic-ischemic rats by intracerebroventricular injection of neural stem/progenitor cells together with chondroitinase ABC. Reprod Sci 2008; 15: 613-620.
37. Zheng T, Marshall Ii GP Jr, Chen KA, Laywell ED,. Transplantation of neural stem/progenitor cells into developing and adult CNS. Methods Mol Biol 2009; 482: 185-197.
38. Comi AM, Cho E, Mulholland JD, et al. Neural stem cells reduce brain injury after unilateral carotid ligation. Pediatr Neurol 2008; 38: 86-92.
39. Titomanlio L, Bouslama M, Le Verche V, et al. Implanted neurosphere-derived precursors promote recovery after neonatal excitotoxic brain injury. Stem Cells Dev 2011; 20: 865-879.
40. van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ,. Mesenchymal stem cell treatment after neonatal hypoxic-ischemic brain injury improves behavioral outcome and induces neuronal and oligodendrocyte regeneration. Brain Behav Immun 2010; 24: 387-393.
41. van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ,. Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage. Pediatr Res 2010; 68: 419-422.
42. Lee HJ, Lim IJ, Lee MC, Kim SU,. Human neural stem cells genetically modified to overexpress brain-derived neurotrophic factor promote functional recovery and neuroprotection in a mouse stroke model. J Neurosci Res 2010; 88: 3282-3294.
43. Alvarez-Buylla A, Temple S,. Stem cells in the developing and adult nervous system. J Neurobiol 1998; 36: 105-110.
44. Gage FH,. Mammalian neural stem cells. Science 2000; 287: 1433-1438.
45. Weiss S, Reynolds BA, Vescovi AL, et al. Is there a neural stem cell in the mammalian forebrain? Trends Neurosci 1996; 19: 387-393.
46. Gritti A, Bonfanti L, Doetsch F, et al. Multipotent neural stem cells reside into the rostral extension and olfactory bulb of adult rodents. J Neurosci 2002; 22: 437-445.
47. Johe KK, Hazel TG, Muller T, et al. Single factors direct the differentiation of stem cells from the fetal and adult central nervous system. Genes Dev 1996; 10: 3129-3140.
48. Reynolds BA, Weiss S,. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992; 255: 1707-1710.
49. Reynolds BA, Weiss S,. Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol 1996; 175: 1-13.
50. Englund U, Bjorklund A, Wictorin K, et al. Grafted neural stem cells develop into functional pyramidal neurons and integrate into host cortical circuitry. Proc Natl Acad Sci U S A 2002; 99: 17089-17094.
51. Scheffler B, Schmandt T, Schroder W, et al. Functional network integration of embryonic stem cell-derived astrocytes in hippocampal slice cultures. Development 2003; 130: 5533-5541.
52. Corti S, Locatelli F, Papadimitriou D, et al. Multipotentiality, homing properties, and pyramidal neurogenesis of CNS-derived LeX(ssea-1)+/CXCR4+ stem cells. FASEB J 2005; 19: 1860-1862.
53. Bjorklund LM, Sanchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A 2002; 99: 2344-2349.
54. Carson CT, Aigner S, Gage FH,. Stem cells: the good, bad and barely in control. Nat Med 2006; 12: 1237-1238.
55. Chung S, Shin BS, Hedlund E, et al. Genetic selection of sox1GFP-expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation. J Neurochem 2006; 97: 1467-1480.
56. Takahashi K, Yamanaka S,. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
57. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
58. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
59. Salewski RP, Eftekharpour E, Fehlings MG,. Are induced pluripotent stem cells the future of cell-based regenerative therapies for spinal cord injury? J Cell Physiol 2010; 222: 515-521.
60. Vierbuchen T, Ostermeier A, Pang ZP, et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010; 463: 1035-1041.
61. Szabo E, Rampalli S, Risueno RM, et al. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 2010; 468: 521-526.
62. Kohyama J, Abe H, Shimazaki T, et al. Brain from bone: efficient "meta-differentiation" of marrow stroma-derived mature osteoblasts to neurons with Noggin or a demethylating agent. Differentiation 2001; 68: 235-244.
63. Dezawa M, Kanno H, Hoshino M, et al. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest 2004; 113: 1701-1710.
64. Woodbury D, Schwarz EJ, Prockop DJ, Black IB,. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 2000; 61: 364-370.
65. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol 2000; 164: 247-256.
66. Suzuki H, Taguchi T, Tanaka H, et al. Neurospheres induced from bone marrow stromal cells are multipotent for differentiation into neuron, astrocyte, and oligodendrocyte phenotypes. Biochem Biophys Res Commun 2004; 322: 918-922.
67. Hermann A, Liebau S, Gastl R, et al. Comparative analysis of neuroectodermal differentiation capacity of human bone marrow stromal cells using various conversion protocols. J Neurosci Res 2006; 83: 1502-1514.
68. Montzka K, Lassonczyk N, Tschoke B, et al. Neural differentiation potential of human bone marrow-derived mesenchymal stromal cells: misleading marker gene expression. BMC Neurosci 2009; 10: 16.
69. Lu P, Blesch A, Tuszynski MH,. Induction of bone marrow stromal cells to neurons: differentiation, transdifferentiation, or artifact? J Neurosci Res 2004; 77: 174-191.
70. Neuhuber B, Gallo G, Howard L, et al. Reevaluation of in vitro differentiation protocols for bone marrow stromal cells: disruption of actin cytoskeleton induces rapid morphological changes and mimics neuronal phenotype. J Neurosci Res 2004; 77: 192-204.
71. Bertani N, Malatesta P, Volpi G, et al. Neurogenic potential of human mesenchymal stem cells revisited: analysis by immunostaining, time-lapse video and microarray. J Cell Sci 2005; 118: 3925-3936.
72. Choi CB, Cho YK, Prakash KV, et al. Analysis of neuron-like differentiation of human bone marrow mesenchymal stem cells. Biochem Biophys Res Commun 2006; 350: 138-146.
73. Pappa KI, Anagnou NP,. Novel sources of fetal stem cells: where do they fit on the developmental continuum? Regen Med 2009; 4: 423-433.
74. Kaplan JM, Youd ME, Lodie TA,. Immunomodulatory activity of mesenchymal stem cells. Curr Stem Cell Res Ther (in press).
75. Sato K, Ozaki K, Mori M, et al. Mesenchymal stromal cells for graft-versus-host disease: basic aspects and clinical outcomes. J Clin Exp Hematop 2010; 50: 79-89.
76. Lee MW, Yang MS, Park JS, et al. Isolation of mesenchymal stem cells from cryopreserved human umbilical cord blood. Int J Hematol 2005; 81: 126-130.
77. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004; 104: 2752-2760.
78. Broxmeyer HE,. Umbilical cord transplantation: epilogue. Semin Hematol 2010; 47: 97-103.
79. Kurtzberg J,. Update on umbilical cord blood transplantation. Curr Opin Pediatr 2009; 21: 22-29.
80. Kogler G, Sensken S, Airey JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004; 200: 123-135.
81. Pimentel-Coelho PM, Magalhaes ES, Lopes LM, et al. Human cord blood transplantation in a neonatal rat model of hypoxic-ischemic brain damage: functional outcome related to neuroprotection in the striatum. Stem Cells Dev 2010; 19: 351-358.
82. Meier C, Middelanis J, Wasielewski B, et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr Res 2006; 59: 244-249.
83. Yasuhara T, Hara K, Maki M, et al. Mannitol facilitates neurotrophic factor up-regulation and behavioural recovery in neonatal hypoxic-ischaemic rats with human umbilical cord blood grafts. J Cell Mol Med 2010; 14: 914-921.
84. de Paula S, Vitola AS, Greggio S, et al. Hemispheric brain injury and behavioral deficits induced by severe neonatal hypoxia-ischemia in rats are not attenuated by intravenous administration of human umbilical cord blood cells. Pediatr Res 2009; 65: 631-635.
85. Markov V, Kusumi K, Tadesse MG, et al. Identification of cord blood-derived mesenchymal stem/stromal cell populations with distinct growth kinetics, differentiation potentials, and gene expression profiles. Stem Cells Dev 2007; 16: 53-73.
86. Tondreau T, Meuleman N, Delforge A, et al. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem Cells 2005; 23: 1105-1112.
87. Gao F, Wu DQ, Hu YH, et al. In vitro cultivation of islet-like cell clusters from human umbilical cord blood-derived mesenchymal stem cells. Transl Res 2008; 151: 293-302.
88. Haase A, Olmer R, Schwanke K, et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 2009; 5: 434-441.
89. Das H, Abdulhameed N, Joseph M, et al. Ex vivo nanofiber expansion and genetic modification of human cord blood-derived progenitor/stem cells enhances vasculogenesis. Cell Transplant 2009; 18: 305-318.
90. Buzanska L, Jurga M, Stachowiak EK, et al. Neural stem-like cell line derived from a nonhematopoietic population of human umbilical cord blood. Stem Cells Dev 2006; 15: 391-406.
91. Jang YK, Park JJ, Lee MC, et al. Retinoic acid-mediated induction of neurons and glial cells from human umbilical cord-derived hematopoietic stem cells. J Neurosci Res 2004; 75: 573-584.
92. Broxmeyer HE,. Will iPS cells enhance therapeutic applicability of cord blood cells and banking? Cell Stem Cell 2010; 6: 21-24.
93. Rocha V, Wagner JE Jr, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000; 342: 1846-1854.
94. Borlongan CV, Hadman M, Sanberg CD, Sanberg PR,. Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. Stroke 2004; 35: 2385-2389.
95. Vendrame M, Cassady J, Newcomb J, et al. Infusion of human umbilical cord blood cells in a rat model of stroke dose-dependently rescues behavioral deficits and reduces infarct volume. Stroke 2004; 35: 2390-2395.
96. Baksh D, Yao R, Tuan RS,. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 2007; 25: 1384-1392.
97. Fujiwara Y, Tanaka N, Ishida O, et al. Intravenously injected neural progenitor cells of transgenic rats can migrate to the injured spinal cord and differentiate into neurons, astrocytes and oligodendrocytes. Neurosci Lett 2004; 366: 287-291.
98. Danielyan L, Schafer R, von Ameln-Mayerhofer A, et al. Intranasal delivery of cells to the brain. Eur J Cell Biol 2009; 88: 315-324.
99. Stroemer P, Patel S, Hope A, et al. The neural stem cell line CTX0E03 promotes behavioral recovery and endogenous neurogenesis after experimental stroke in a dose-dependent fashion. Neurorehabil Neural Repair 2009; 23: 895-909.
100. Schwarz SC, Schwarz J,. Translation of stem cell therapy for neurological diseases. Transl Res 2010; 156: 155-160.
101. Bjarkam CR, Glud AN, Margolin L, et al. Safety and function of a new clinical intracerebral microinjection instrument for stem cells and therapeutics examined in the Gottingen minipig. Stereotact Funct Neurosurg 2010; 88: 56-63.
102. Guillaume DJ, Huhn SL, Selden NR, Steiner RD,. Cellular therapy for childhood neurodegenerative disease. Part I: Rationale and preclinical studies. Neurosurg Focus 2008; 24: E22.
103. van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ,. Repeated mesenchymal stem cell treatment after neonatal hypoxia-ischemia has distinct effects on formation and maturation of new neurons and oligodendrocytes leading to restoration of damage, corticospinal motor tract activity, and sensorimotor function. J Neurosci 2010; 30: 9603-9611.
104. Sykova E, Jendelova P,. Migration, fate and in vivo imaging of adult stem cells in the CNS. Cell Death Differ 2007; 14: 1336-1342.
105. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Circulation 2007; 115: e478-e534.
106. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38: 1655-1711.
107. Chen J, Li Y, Katakowski M, et al. Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J Neurosci Res 2003; 73: 778-786.
108. Okazaki T, Magaki T, Takeda M, et al. Intravenous administration of bone marrow stromal cells increases survivin and Bcl-2 protein expression and improves sensorimotor function following ischemia in rats. Neurosci Lett 2008; 430: 109-114.
109. Zhang C, Li Y, Chen J, et al. Bone marrow stromal cells upregulate expression of bone morphogenetic proteins 2 and 4, gap junction protein connexin-43 and synaptophysin after stroke in rats. Neuroscience 2006; 141: 687-695.
110. Ferriero DM,. Neonatal brain injury. N Engl J Med 2004; 351: 1985-1995.
111. Degos V, Favrais G, Kaindl AM, et al. Inflammation processes in perinatal brain damage. J Neural Transm 2010; 117: 1009-1017.
112. Kounami S, Aoyagi N, Nakayama K, et al. Fatal pulmonary thromboembolism after a second course of high-dose chemotherapy with autologous peripheral blood stem cell transplantation. Pediatr Transplant 2003; 7: 400-403.
113. Morales IJ, Anderson PM, Tazelaar HD, Wylam ME,. Pulmonary cytolytic thrombi: unusual complication of hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2003; 25: 89-92.
114. Walczak P, Zhang J, Gilad AA, et al. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke 2008; 39: 1569-1574.
115. Nishino H, Borlongan CV,. Restoration of function by neural transplantation in the ischemic brain. Prog Brain Res 2000; 127: 461-476.
116. Rosenkranz K, Kumbruch S, Lebermann K, et al. The chemokine SDF-1/CXCL12 contributes to the "homing" of umbilical cord blood cells to a hypoxic-ischemic lesion in the rat brain. J Neurosci Res 2010; 88: 1223-1233.
117. Abe K,. Therapeutic potential of neurotrophic factors and neural stem cells against ischemic brain injury. J Cereb Blood Flow Metab 2000; 20: 1393-1408.
118. Imitola J, Raddassi K, Park KI, et al. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A 2004; 101: 18117-18122.
119. Duncan ID,. Oligodendrocytes and stem cell transplantation: their potential in the treatment of leukoencephalopathies. J Inherit Metab Dis 2005; 28: 357-368.
120. McKenzie IA, Biernaskie J, Toma JG, et al. Skin-derived precursors generate myelinating Schwann cells for the injured and dysmyelinated nervous system. J Neurosci 2006; 26: 6651-6660.
121. Tran KD, Ho A, Jandial R,. Stem cell transplantation methods. Adv Exp Med Biol 2010; 671: 41-57.
122. Guzman R, Uchida N, Bliss TM, et al. Long-term monitoring of transplanted human neural stem cells in developmental and pathological contexts with MRI. Proc Natl Acad Sci U S A 2007; 104: 10211-10216.
123. Neri M, Maderna C, Cavazzin C, et al. Efficient in vitro labeling of human neural precursor cells with superparamagnetic iron oxide particles: relevance for in vivo cell tracking. Stem Cells 2008; 26: 505-516.
124. Manganas LN, Zhang X, Li Y, et al. Magnetic resonance spectroscopy identifies neural progenitor cells in the live human brain. Science 2007; 318: 980-985.
125. Politi LS,. MR-based imaging of neural stem cells. Neuroradiology 2007; 49: 523-534.
126. Deng J, Petersen BE, Steindler DA, et al. Mesenchymal stem cells spontaneously express neural proteins in culture and are neurogenic after transplantation. Stem Cells 2006; 24: 1054-1064.
127. Nag S, Kapadia A, Stewart DJ,. Molecular pathogenesis of blood-brain barrier breakdown in acute brain injury. Neuropathol Appl Neurobiol 2011; 37: 3-23.
128. Coyne TM, Marcus AJ, Woodbury D, Black IB,. Marrow stromal cells transplanted to the adult brain are rejected by an inflammatory response and transfer donor labels to host neurons and glia. Stem Cells 2006; 24: 2483-2492.
129. Spaggiari GM, Capobianco A, Abdelrazik H, et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111: 1327-1333.
130. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-719.
131. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403-414.
132. Freeman TB, Cicchetti F, Hauser RA, et al. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc Natl Acad Sci U S A 2000; 97: 13877-13882.
133. Keene CD, Sonnen JA, Swanson PD, et al. Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 2007; 68: 2093-2098.
134. Tai YT, Svendsen CN,. Stem cells as a potential treatment of neurological disorders. Curr Opin Pharmacol 2004; 4: 98-104.
135. Lepore AC, Neuhuber B, Connors TM, et al. Long-term fate of neural precursor cells following transplantation into developing and adult CNS. Neuroscience 2006; 142: 287-304.
136. Hess PG,. Risk of tumorigenesis in first-in-human trials of embryonic stem cell neural derivatives: ethics in the face of long-term uncertainty. Account Res 2009; 16: 175-198.
137. Low CB, Liou YC, Tang BL,. Neural differentiation and potential use of stem cells from the human umbilical cord for central nervous system transplantation therapy. J Neurosci Res 2008; 86: 1670-1679.
138. Gruen L, Grabel L,. Concise review: scientific and ethical roadblocks to human embryonic stem cell therapy. Stem Cells 2006; 24: 2162-2169.
139. Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009; 6: e1000029.
140. Windrem MS, Nunes MC, Rashbaum WK, et al. Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain. Nat Med 2004; 10: 93-97.
141. Tahraoui SL, Marret S, Bodenant C, et al. Central role of microglia in neonatal excitotoxic lesions of the murine periventricular white matter. Brain Pathol 2001; 11: 56-71.
142. Lodygensky GA, Vasung L, Sizonenko SV, Huppi PS,. Neuroimaging of cortical development and brain connectivity in human newborns and animal models. J Anat 2010; 217: 418-428.
143. Yager JY, Ashwal S,. Animal models of perinatal hypoxic-ischemic brain damage. Pediatr Neurol 2009; 40: 156-167.
144. Scafidi J, Fagel DM, Ment LR, Vaccarino FM,. Modeling premature brain injury and recovery. Int J Dev Neurosci 2009; 27: 863-871.
145. Dihne M, Bernreuther C, Hagel C, et al. Embryonic stem cell-derived neuronally committed precursor cells with reduced teratoma formation after transplantation into the lesioned adult mouse brain. Stem Cells 2006; 24: 1458-1466.
146. Mueller D, Shamblott MJ, Fox HE, et al. Transplanted human embryonic germ cell-derived neural stem cells replace neurons and oligodendrocytes in the forebrain of neonatal mice with excitotoxic brain damage. J Neurosci Res 2005; 82: 592-608.
147. Daadi MM, Davis AS, Arac A, et al. Human neural stem cell grafts modify microglial response and enhance axonal sprouting in neonatal hypoxic-ischemic brain injury. Stroke 2010; 41: 516-523.
148. Yasuhara T, Hara K, Maki M, et al. Intravenous grafts recapitulate the neurorestoration afforded by intracerebrally delivered multipotent adult progenitor cells in neonatal hypoxic-ischemic rats. J Cereb Blood Flow Metab 2008; 28: 1804-1810.
149. Li Y, Chen J, Chen XG, et al. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology 2002; 59: 514-523.
150. Shen LH, Li Y, Chen J, et al. One-year follow-up after bone marrow stromal cell treatment in middle-aged female rats with stroke. Stroke 2007; 38: 2150-2156.
151. Bondolfi L, Ermini F, Long JM, et al. Impact of age and caloric restriction on neurogenesis in the dentate gyrus of C57BL/6 mice. Neurobiol Aging 2004; 25: 333-340.
152. Kuhn HG, Dickinson-Anson H, Gage FH,. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J Neurosci 1996; 16: 2027-2033.
153. Leuner B, Kozorovitskiy Y, Gross CG, Gould E,. Diminished adult neurogenesis in the marmoset brain precedes old age. Proc Natl Acad Sci U S A 2007; 104: 17169-17173.
154. Zigova T, Song S, Willing AE, et al. Human umbilical cord blood cells express neural antigens after transplantation into the developing rat brain. Cell Transplant 2002; 11: 265-274.
155. Wurmser AE, Nakashima K, Summers RG, et al. Cell fusion-independent differentiation of neural stem cells to the endothelial lineage. Nature 2004; 430: 350-356.
156. Kelly S, Bliss TM, Shah AK, et al. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc Natl Acad Sci U S A 2004; 101: 11839-11844.
157. Park KI, Lachyankar M, Nissim S, Snyder EY,. Neural stem cells for CNS repair: state of the art and future directions. Adv Exp Med Biol 2002; 506: 1291-1296.
158. Ourednik J, Ourednik V, Lynch WP, et al. Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat Biotechnol 2002; 20: 1103-1110.
159. Pluchino S, Quattrini A, Brambilla E, et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 2003; 422: 688-694.
160. Sinden JD, Rashid-Doubell F, Kershaw TR, et al. Recovery of spatial learning by grafts of a conditionally immortalized hippocampal neuroepithelial cell line into the ischaemia-lesioned hippocampus. Neuroscience 1997; 81: 599-608.
161. Aharonowiz M, Einstein O, Fainstein N, et al. Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis. PLoS One 2008; 3: e3145.
162. Ben-Hur T,. Immunomodulation by neural stem cells. J Neurol Sci 2008; 265: 102-104.
163. Einstein O, Ben-Hur T,. The changing face of neural stem cell therapy in neurologic diseases. Arch Neurol 2008; 65: 452-456.
164. Locatelli F, Bersano A, Ballabio E, et al. Stem cell therapy in stroke. Cell Mol Life Sci 2009; 66: 757-772.
165. Bacigaluppi M, Pluchino S, Peruzzotti Jametti L, et al. Delayed post-ischaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms. Brain 2009; 132: 2239-2251.
166. Pluchino S, Cusimano M, Bacigaluppi M, Martino G,. Remodelling the injured CNS through the establishment of atypical ectopic perivascular neural stem cell niches. Arch Ital Biol 2010; 148: 173-183.
167. Lee ST, Chu K, Jung KH, et al. Anti-inflammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic stroke. Brain 2008; 131: 616-629.
168. Prowse AB, Chong F, Gray PP, Munro TP,. Stem cell integrins: implications for ex-vivo culture and cellular therapies. Stem Cell Res 2011; 6: 1-12.
169. Keirstead HS, Nistor G, Bernal G, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci 2005; 25: 4694-4705.
170. Mathieu P, Battista D, Depino A, et al. The more you have, the less you get: the functional role of inflammation on neuronal differentiation of endogenous and transplanted neural stem cells in the adult brain. J Neurochem 2010; 112: 1368-1385.
171. Pollock K, Stroemer P, Patel S, et al. A conditionally immortal clonal stem cell line from human cortical neuroepithelium for the treatment of ischemic stroke. Exp Neurol 2006; 199: 143-155.
172. Tamaki SJ, Jacobs Y, Dohse M, et al. Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. Cell Stem Cell 2009; 5: 310-319.
173. Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005; 352: 2069-2081.
174. Sun J, Allison J, McLaughlin C, et al. Differences in quality between privately and publicly banked umbilical cord blood units: a pilot study of autologous cord blood infusion in children with acquired neurologic disorders. Transfusion 2010; 50: 1980-1987.
175. Gluckman E, Rocha V, Chastang C,. Peripheral stem cells in bone marrow transplantation. Cord blood stem cell transplantation. Baillieres Best Pract Res Clin Haematol 1999; 12: 279-292.
176. Kaufman DS, Thomson JA,. Human ES cells-haematopoiesis and transplantation strategies. J Anat 2002; 200: 243-248.
177. Zhang SC,. Embryonic stem cells for neural replacement therapy: prospects and challenges. J Hematother Stem Cell Res 2003; 12: 625-634.
178. Muller FJ, Snyder EY, Loring JF,. Gene therapy: can neural stem cells deliver? Nat Rev Neurosci 2006; 7: 75-84.
179. Horita Y, Honmou O, Harada K, et al. Intravenous administration of glial cell line-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in the adult rat. J Neurosci Res 2006; 84: 1495-1504.
180. Elsayed MH, Hogan TP, Shaw PL, Castro AJ,. Use of fetal cortical grafts in hypoxic-ischemic brain injury in neonatal rats. Exp Neurol 1996; 137: 127-141.
181. Jansen EM, Solberg L, Underhill S, et al. Transplantation of fetal neocortex ameliorates sensorimotor and locomotor deficits following neonatal ischemic-hypoxic brain injury in rats. Exp Neurol 1997; 147: 487-497.
182. Ma J, Wang Y, Yang J, et al. Treatment of hypoxic-ischemic encephalopathy in mouse by transplantation of embryonic stem cell-derived cells. Neurochem Int 2007; 51: 57-65.
183. Lee JP, Jeyakumar M, Gonzalez R, et al. Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med 2007; 13: 439-447.
184. Lee JA, Kim BI, Jo CH, et al. Mesenchymal stem-cell transplantation for hypoxic-ischemic brain injury in neonatal rat model. Pediatr Res 2010; 67: 42-46.